NeuroBo Pharmaceuticals Announces Acceptance Of Two General Posters And One ePoster Theater Discussion Of Its Novel GLP1R And GCGR Dual Agonist, DA-1726, At The American Diabetes Association 83rd Scientific Sessions
Portfolio Pulse from Benzinga Newsdesk
NeuroBo Pharmaceuticals' novel oxyntomodulin analogue, DA-1726, has been accepted for one ePoster theater discussion and two general poster presentations at the American Diabetes Association 83rd Scientific Sessions. The company plans to advance DA-1726 through the IND process in H2 2023 and initiate a phase 1a safety study in H1 2024.
June 13, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroBo Pharmaceuticals' DA-1726 has been accepted for presentations at the ADA 83rd Scientific Sessions, with plans to advance through the IND process in H2 2023 and initiate a phase 1a safety study in H1 2024.
The acceptance of NeuroBo Pharmaceuticals' DA-1726 for presentations at the prestigious ADA 83rd Scientific Sessions indicates the strength of the preclinical data generated so far. This positive development, along with the company's plans to advance through the IND process and initiate a phase 1a safety study, is likely to have a positive short-term impact on the stock price of NeuroBo Pharmaceuticals (NRBO).
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100